8 completed. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
Follow Drug Eruptions: new trials by email Literature Review of Drug Eruptions trials Research Report on Drug Eruptions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NATIENS: Optimal Management and Mechanisms of SJS/TEN Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4 - Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | Phase 3 | Completed | Vanderbilt University Medical Center | 2 | 2023-03-21 | 2025-12-17 |
| Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome Onco-Repair/ Placebo - Grade 2 Hand-foot Syndrom | Phase 3 | Completed | Quanta Medical | 72 | 2018-07-12 | 2019-09-06 |
| Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer Traditional Chinese Medicine Formula LC09, Placebo - Hand Foot Syndrome | Phase 3 | Completed | China-Japan Friendship Hospital | 156 | 2015-04-01 | 2019-07-25 |
| S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. Capecitabine, Teysuno, Bevacizumab - Colorectal Cancer, Metastases | Phase 3 | Completed | Dutch Colorectal Cancer Group | 161 | 2013-12-01 | 2018-03-14 |
| Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Intravenous immunoglobulin - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Phase 3 | Completed | Nihon Pharmaceutical Co., Ltd | 10 | 2012-10-01 | 2014-07-02 |
| F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer antiperspirant cream F511, pegylated liposomal doxorubicin hydrochloride - Breast Cancer, Palmar-plantar Erythrodysesthesia | Phase 3 | Completed | Swiss Cancer Institute | 91 | 2009-09-01 | 2019-05-15 |
| Study of Pyridoxine for Hand-Foot Syndrome Pyridoxine, Placebo - Hand-foot Syndrome | Phase 3 | Completed | Asan Medical Center | 389 | 2004-06-01 | 2014-02-25 |
| Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Cultivated conjunctival transplantation - Pterygium, Ocular Surface Disease | Phase 3 | Completed | Singapore National Eye Centre | 80 | 2001-10-01 | 2010-01-13 |
Hand-Foot Syndrome (5) · Stevens-Johnson Syndrome (3) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Colorectal Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pterygium (1)
Chemically-Induced Disorders (8) · Dermatitis (8) · Drug Hypersensitivity (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Drug-Related Side Effects and Adverse Reactions (7) · Erythema (3) · Erythema Multiforme (3) · Hypersensitivity (3) · Hypersensitivity, Delayed (3) · Immune System Diseases (3) · Mouth Diseases (3) · Skin Diseases, Vesiculobullous (3) · Stomatitis (3)
Bevacizumab (1) · Capecitabine (1) · Etanercept (1) · Immunoglobulins, Intravenous (1) · Pyridoxine (1) · S 1 (combination) (1) · tegafur-gimeracil-oteracil (1)
Asan Medical Center (1) · China-Japan Friendship Hospital (1) · Dutch Colorectal Cancer Group (1) · Nihon Pharmaceutical Co., Ltd (1) · Quanta Medical (1) · Singapore National Eye Centre (1) · Swiss Cancer Institute (1) · Vanderbilt University Medical Center (1)
France (1) · Japan (1) · Netherlands (1) · Singapore (1) · Switzerland (1) · United States (1)
Cornelis JA Punt, Prof MD PhD (1) · Donald T Tan, FRCS (1) · Elizabeth J Phillips, MD (1) · Leonard P Ang, FRCS (1) · Thomas Ruhstaller, MD (1) · Yoon-Koo Kang (1)
PMID 15161841, PMID 15287367, PMID 20625131, PMID 24656636, PMID 28383633, PMID 30782413, PMID 32597691